Anti-Anginal Efficacy of Zibotentan in the Coronary Slow-Flow Phenomenon
Open Access
- 27 February 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1337
Abstract
Background: Patients with coronary microvascular disorders often experience recurrent angina for which there are limited evidence-based therapies. These patients have been found to exhibit increased plasma levels of endothelin; thus, selective endothelin–A (Et-A) receptor blockers such as zibotentan may be an effective anti-anginal therapy in these patients. The study evaluated the impact of a 10 mg daily dose of zibotentan on spontaneous angina episodes in patients with the coronary slow-flow phenomenon who had refractory angina (i.e., experiencing angina at least three times/week despite current anti-anginal therapy). Methods: Using a randomized, double-blind, placebo-controlled, crossover trial design with 4-week treatment periods, 18 patients (63.2 ± 9.9 years, 33% females) were recruited. The primary endpoint was angina frequency as measured by an angina diary, with secondary endpoints including nitrate consumption, angina duration/severity and the Seattle Angina Questionnaire (SAQ) domains. Results: During the 4 weeks of therapy, angina frequency significantly improved with zibotentan therapy (placebo 41.4 (58.5) vs. zibotentan 29.2 (31.6), p < 0.05), and sublingual nitrate consumption significantly reduced (placebo 11.8 (15.2) vs. zibotentan 8.8 (12.9), p < 0.05. Conclusions: Zibotentan improved the frequency of spontaneous angina episodes and reduced sublingual nitrate consumption in patients unresponsive to standard anti-anginal therapy.Keywords
Funding Information
- AstraZeneca UK Ltd.
- The Hospital Research Foundation Group
This publication has 33 references indexed in Scilit:
- Interpretation of the Seattle Angina Questionnaire as an Outcome Measure in Clinical Trials and Clinical CareJAMA Cardiology, 2021
- Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic OptionsJACC, 2018
- Coronary Microvascular Dysfunction, Microvascular Angina, and Treatment StrategiesJACC: Cardiovascular Imaging, 2015
- Potential mechanisms of the acute coronary syndrome presentation in patients with the coronary slow flow phenomenon — Insight from a plasma proteomic approachInternational Journal of Cardiology, 2012
- The relation between coronary flow rate, plasma endothelin-1 concentrations, and clinical characteristics in patients with normal coronary arteriesCardiovascular Revascularization Medicine, 2008
- Elevated plasma endothelin-1 levels in coronary sinus during rapid right atrial pacing in patients with slow coronary flowInternational Journal of Cardiology, 2004
- The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenonJACC, 2004
- Slow coronary flow: Clinical and histopathological features in patients with otherwise normal epicardial coronary arteriesCatheterization and Cardiovascular Diagnosis, 1996
- Long‐term clinical course of patients with angina and angiographically normal coronary arteriesClinical Cardiology, 1991
- Intracoronary endothelin induces myocardial ischemia by small vessel constriction in the dogThe American Journal of Cardiology, 1989